Variable | n | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |||
Gender | Male | 61 | 1 (reference) | 0.657 | Â | Â |
Female | 12 | 0.807 (0.313–2.080) |  | |||
Age (y) | < 65 | 26 | 1 (reference) | 0.422 |  |  |
≥ 65 | 47 | 1.340 (0.656–2.738) |  | |||
Performance status | 0 or 1 | 57 | 1 (reference) | 0.004 a | 1 (reference) | 0.066 |
2 | 16 | 2.975 (1.431–6.186) | 2.051 (0.954–4.410) | |||
Body surface area (m2) | < 1.50 | 30 | 1 (reference) | 0.162 |  |  |
≥ 1.50 | 43 | 1.664 (0.815–3.398) |  | |||
eGFR (ml/min/1.73m2) | < 60 | 13 | 1 (reference) | 0.838 |  |  |
≥ 60 | 60 | 1.096 (0.455–2.643) |  | |||
Tumor size (cm) | < 5 | 35 | 1 (reference) | < 0.001 a | 1 (reference) | 0.332 |
≥ 5 | 38 | 3.755 (1.784–7.903) | 1.638 (0.605–4.436) | |||
Post-dCRT chemotherapy | – | 17 | 1 (reference) | 0.646 |  |  |
+ | 56 | 0.823 (0.358–1.891) |  | |||
Histological type | Differentiated | 64 | 1 (reference) | 0.876 | Â | Â |
Un-differentiated | 9 | 1.079 (0.418–2.782) |  | |||
Clinical stage in UICC 8th edition | I (cT1b) - III | 38 | 1 (reference) | < 0.001 a | 1 (reference) | 0.006 a |
IVA or IVB (cM1-lym) | 35 | 5.177 (2.448–10.946) | 4.085 (1.488–11.211) | |||
Radiation dose (Gy) | < 57 | 13 | 1 (reference) | 0.670 |  |  |
≥ 57 | 60 | 1.229 (0.477–3.169) |  | |||
Nedaplatin dose intensity in dCRT (%) | < 90 | 45 | 1 (reference) | 0.360 |  |  |
≥ 90 | 28 | 0.716 (0.351–1.463) |  | |||
5-fluorouracil dose intensity in dCRT (%) | < 90 | 47 | 1 (reference) | 0.130 |  |  |
≥ 90 | 26 | 0.556 (0.261–1.188) |  | |||
SLFN11 expression | Low (< 51) | 37 | 1 (reference) | 0.018 a | 1 (reference) | 0.001 a |
(H-score) | High (≥ 51) | 36 | 0.438 (0.221–0.866) | 0.295 (0.143–0.605) |